Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.

Autoimmune diseases are often treated by glucocorticoids and immunosuppressive drugs that could increase the risk for infection, which in turn deteriorate disease and cause mortality. Low-dose IL-2 (Ld-IL2) therapy emerges as a new treatment for a wide range of autoimmune diseases. To examine its in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pengcheng Zhou, Jiali Chen, Jing He, Ting Zheng, Joseph Yunis, Victor Makota, Yannick O Alexandre, Fang Gong, Xia Zhang, Wuxiang Xie, Yuhui Li, Miao Shao, Yanshan Zhu, Jane E Sinclair, Miao Miao, Yaping Chen, Kirsty R Short, Scott N Mueller, Xiaolin Sun, Di Yu, Zhanguo Li
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/6892f12d515d4852b12e973d2e669c97
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6892f12d515d4852b12e973d2e669c97
record_format	dspace
spelling	oai:doaj.org-article:6892f12d515d4852b12e973d2e669c972021-12-02T20:00:03ZLow-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.1553-73661553-737410.1371/journal.ppat.1009858https://doaj.org/article/6892f12d515d4852b12e973d2e669c972021-10-01T00:00:00Zhttps://doi.org/10.1371/journal.ppat.1009858https://doaj.org/toc/1553-7366https://doaj.org/toc/1553-7374Autoimmune diseases are often treated by glucocorticoids and immunosuppressive drugs that could increase the risk for infection, which in turn deteriorate disease and cause mortality. Low-dose IL-2 (Ld-IL2) therapy emerges as a new treatment for a wide range of autoimmune diseases. To examine its influence on infection, we retrospectively studied 665 patients with systemic lupus erythematosus (SLE) including about one third receiving Ld-IL2 therapy, where Ld-IL2 therapy was found beneficial in reducing the incidence of infections. In line with this clinical observation, IL-2 treatment accelerated viral clearance in mice infected with influenza A virus or lymphocytic choriomeningitis virus (LCMV). Noticeably, despite enhancing anti-viral immunity in LCMV infection, IL-2 treatment exacerbated CD8+ T cell-mediated immunopathology. In summary, Ld-IL2 therapy reduced the risk of infections in SLE patients and enhanced the control of viral infection, but caution should be taken to avoid potential CD8+ T cell-mediated immunopathology.Pengcheng ZhouJiali ChenJing HeTing ZhengJoseph YunisVictor MakotaYannick O AlexandreFang GongXia ZhangWuxiang XieYuhui LiMiao ShaoYanshan ZhuJane E SinclairMiao MiaoYaping ChenKirsty R ShortScott N MuellerXiaolin SunDi YuZhanguo LiPublic Library of Science (PLoS)articleImmunologic diseases. AllergyRC581-607Biology (General)QH301-705.5ENPLoS Pathogens, Vol 17, Iss 10, p e1009858 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5
spellingShingle	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5 Pengcheng Zhou Jiali Chen Jing He Ting Zheng Joseph Yunis Victor Makota Yannick O Alexandre Fang Gong Xia Zhang Wuxiang Xie Yuhui Li Miao Shao Yanshan Zhu Jane E Sinclair Miao Miao Yaping Chen Kirsty R Short Scott N Mueller Xiaolin Sun Di Yu Zhanguo Li Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.
description	Autoimmune diseases are often treated by glucocorticoids and immunosuppressive drugs that could increase the risk for infection, which in turn deteriorate disease and cause mortality. Low-dose IL-2 (Ld-IL2) therapy emerges as a new treatment for a wide range of autoimmune diseases. To examine its influence on infection, we retrospectively studied 665 patients with systemic lupus erythematosus (SLE) including about one third receiving Ld-IL2 therapy, where Ld-IL2 therapy was found beneficial in reducing the incidence of infections. In line with this clinical observation, IL-2 treatment accelerated viral clearance in mice infected with influenza A virus or lymphocytic choriomeningitis virus (LCMV). Noticeably, despite enhancing anti-viral immunity in LCMV infection, IL-2 treatment exacerbated CD8+ T cell-mediated immunopathology. In summary, Ld-IL2 therapy reduced the risk of infections in SLE patients and enhanced the control of viral infection, but caution should be taken to avoid potential CD8+ T cell-mediated immunopathology.
format	article
author	Pengcheng Zhou Jiali Chen Jing He Ting Zheng Joseph Yunis Victor Makota Yannick O Alexandre Fang Gong Xia Zhang Wuxiang Xie Yuhui Li Miao Shao Yanshan Zhu Jane E Sinclair Miao Miao Yaping Chen Kirsty R Short Scott N Mueller Xiaolin Sun Di Yu Zhanguo Li
author_facet	Pengcheng Zhou Jiali Chen Jing He Ting Zheng Joseph Yunis Victor Makota Yannick O Alexandre Fang Gong Xia Zhang Wuxiang Xie Yuhui Li Miao Shao Yanshan Zhu Jane E Sinclair Miao Miao Yaping Chen Kirsty R Short Scott N Mueller Xiaolin Sun Di Yu Zhanguo Li
author_sort	Pengcheng Zhou
title	Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.
title_short	Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.
title_full	Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.
title_fullStr	Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.
title_full_unstemmed	Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.
title_sort	low-dose il-2 therapy invigorates cd8+ t cells for viral control in systemic lupus erythematosus.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/6892f12d515d4852b12e973d2e669c97
work_keys_str_mv	AT pengchengzhou lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT jialichen lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT jinghe lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT tingzheng lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT josephyunis lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT victormakota lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT yannickoalexandre lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT fanggong lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT xiazhang lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT wuxiangxie lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT yuhuili lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT miaoshao lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT yanshanzhu lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT janeesinclair lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT miaomiao lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT yapingchen lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT kirstyrshort lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT scottnmueller lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT xiaolinsun lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT diyu lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus AT zhanguoli lowdoseil2therapyinvigoratescd8tcellsforviralcontrolinsystemiclupuserythematosus
_version_	1718375727107145728

Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.

Ejemplares similares